MAAT INDEX

CLAIM #23047 · EMR (EMR) · 2026Q2 earnings call · May 5, 2026 · due Jun 30, 2026

Moving to the third quarter, sales growth is expected to be approximately 5.5% with underlying sales growth of approximately 5%.

Michael Baughman · CFO

PENDING
graded after results covering Jun 30, 2026 are reported

In context

y, we expect a net neutral impact from the removal of IEBA tariffs, as this benefit is offset by increases in Section 1 and 232 tariffs as well as freight costs. Finally, our earnings and cash flow guidance excludes any benefit of potential tariff refunds. For the full year, we expect FX to be a tailwind to sales of approximately 1.5% and GAAP sales to increase approximately 4.5%. We still expect adjusted segment EBITDA margin of approximately 28% and free cash flow of $3.5 billion to $3.6 billion. We are raising the bottom and midpoint of our 2026 adjusted EPS guide and now expect $6.45 to $6.55. We still expect to return approximately $2.2 billion to shareholders through $1.2 billion in dividends and $1.0 billion of share repurchase, of which we completed $542 million in the first half. Moving to the third quarter, sales growth is expected to be approximately 5.5% with underlying sales growth of approximately 5%. We expect adjusted segment EBITDA margin of approximately 28% and adjusted EPS of $1.65 to $1.70. With that, I would like to turn the call back to the operator for Q&A. Operator: We will now open the call for questions. Thank you. Our first question is from Scott Davis with Melius Research. Scott Davis: Hey, good afternoon, guys. Hi, Scott. A couple just points to clarify. I thought that detail you gave in the call was pretty thorough, but so we lost about a point in the Middle East, and it sounds like you expect to get about a half of that point back. Is that correct? Is the rest lost revenues, or is there still optionality or potential to regain the remainder of those revenues? Michael J. Baughman: No. I think, Scott, we have seen the disruption in the Middle East, and as we mentioned o

Verify independently

SEC filings for EMR · Claim quote is verbatim from the 2026Q2 earnings call.